Open-label, randomized, multicenter, phase 3, ELAINE 3 study of the efficacy and safety of lasofoxifene plus abemaciclib for treating ER+/HER2-, locally advanced or metastatic breast cancer with an ESR1 mutation.
0
Authors
Matthew Goetz
Matthew Goetz•Massimo Cristofanilli•Senthil Damodaran
